130 related articles for article (PubMed ID: 37982464)
1. Connexin 43 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and Therapeutic Implications.
Fernandez-Flores A; Varela-Vazquez A; Mayan MD; Fonseca E
Am J Dermatopathol; 2023 Dec; 45(12):812-815. PubMed ID: 37982464
[TBL] [Abstract][Full Text] [Related]
2. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
3. CD99 expression in dermatofibrosarcoma protuberans and dermatofibroma.
Kazlouskaya V; Malhotra S; Kabigting FD; Lal K; Elston DM
Am J Dermatopathol; 2014 May; 36(5):392-6. PubMed ID: 24247571
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
Sachdev R; Sundram U
J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
[TBL] [Abstract][Full Text] [Related]
5. Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34.
Kim HJ; Lee JY; Kim SH; Seo YJ; Lee JH; Park JK; Kim MH; Cinn YW; Cho KH; Yoon TY
Br J Dermatol; 2007 Aug; 157(2):319-24. PubMed ID: 17596171
[TBL] [Abstract][Full Text] [Related]
6. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
8. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
9. From Morphea to Dermatofibrosarcoma Protuberans.
Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
[TBL] [Abstract][Full Text] [Related]
10. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
11. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
[No Abstract] [Full Text] [Related]
12. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
13. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatofibrosarcoma protuberans and common fibrous histiocytoma (dermatofibroma).
Weinrach DM; Wang KL; Wiley EL; Laskin WB
Arch Pathol Lab Med; 2004 Oct; 128(10):1136-41. PubMed ID: 15387709
[TBL] [Abstract][Full Text] [Related]
15. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Cribier B; Noacco G; Peltre B; Grosshans E
J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
[TBL] [Abstract][Full Text] [Related]
16. IGFBP7, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Li J; Yu Y; Yang Y; Wang L; Cao J; Liang X; Xiao X; Tu Y; Chen H
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):382-5. PubMed ID: 21492256
[TBL] [Abstract][Full Text] [Related]
17. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in dermatofibroma and dermatofibrosarcoma protuberans.
Adler N; Tsabari C; Sulkes J; Ad-El D; Feinmesser M
J Cutan Pathol; 2008 Jun; 35(6):532-5. PubMed ID: 18201240
[TBL] [Abstract][Full Text] [Related]
19. Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles.
Hsi ED; Nickoloff BJ
J Dermatol Sci; 1996 Jan; 11(1):1-9. PubMed ID: 8867761
[TBL] [Abstract][Full Text] [Related]
20. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
